Mati Gill, AION Labs CEO

Big Phar­ma com­pa­nies join hands with Ama­zon on new Is­rael-based AI in­cu­ba­tor

What do Mer­ck, Pfiz­er, As­traZeneca and Te­va have in com­mon with Ama­zon? As of Wednes­day, they’re all join­ing forces with the Is­rael Biotech Fund to launch a new in­cu­ba­tor for star­tups walk­ing the line be­tween AI and drug de­vel­op­ment — and they’re gear­ing up to make some big in­vest­ments.

AION Labs plans to seed be­tween four and six new biotech com­pa­nies per year, start­ing in ear­ly 2022, CEO Mati Gill told End­points News. The funds should sup­port two to four years of run­way for each start­up.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Associate

Alexandria Real Estate Equities

Cambridge, MA, USA